HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.

AbstractHealth-related quality of life (HRQoL) is a major concern for adults with chronic immune thrombocytopenic purpura (ITP) due to the symptoms associated with the disease and its treatment. This study utilized the ITP-patient assessment questionnaire (ITP-PAQ), a specialized HRQoL questionnaire for ITP, to investigate the humanistic burden of ITP and the impact of romiplostim therapy on HRQoL in two, placebo-controlled, phase 3 clinical trials of splenectomized and non-splenectomized patients. ITP-PAQ was self-administered to ITP patients at baseline, and weeks 4, 12 and 24 of treatment. Splenectomized patients had lower baseline HRQoL scores than non-splenectomized patients in seven of 10 scales (P < 0.05). After 24 weeks of romiplostim therapy, splenectomized patients showed significant improvements over placebo in four of 10 ITP-PAQ Scales (Symptoms, P = 0.0337; Bother, P = 0.0126; Social Activity, P = 0.0145; and Women's Reproductive Health, P = 0.0184). Non-splenectomized patients demonstrated significant improvement over placebo in the Activity Scale (P = 0.0458). Data pooled from the two trials, adjusted for splenectomy status, showed significant improvement for romiplostim-treated patients in six scales; Symptoms, Bother, Activity, Fear, Social Activity and Women's Reproductive Health. These results suggest that adult patients with chronic ITP have improved HRQoL following romiplostim therapy.
AuthorsJames N George, Susan D Mathias, Ronald S Go, Matthew Guo, David H Henry, Roger Lyons, Robert L Redner, Lawrence Rice, Martin R Schipperus (Affiliation: Colleges of Medicine and Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126-0901, USA. james-george at ouhsc.edu)
JournalBritish journal of haematology (Br J Haematol) Vol. 144 Issue 3 Pg. 409-15 (Feb 2009) ISSN: 1365-2141 [Electronic] England
PMID19016720 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Carrier Proteins
  • Receptors, Fc
  • romiplostim
Topics
  • Adult
  • Aged
  • Carrier Proteins (therapeutic use)
  • Chronic Disease
  • Combined Modality Therapy
  • Double-Blind Method
  • Female
  • Health Status Indicators
  • Humans
  • Male
  • Middle Aged
  • Psychometrics
  • Purpura, Thrombocytopenic, Idiopathic (drug therapy, psychology, surgery)
  • Quality of Life
  • Receptors, Fc (therapeutic use)
  • Splenectomy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD